Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-16T14:39:11.411Z Has data issue: false hasContentIssue false
  • English
  • Français

The Effect Of Atipical Antipsychotic Medications In Anorexia Nervosa

Published online by Cambridge University Press:  23 March 2020

M. Barchiesi ,
M. Martellini ,
M.G. Oriani  and
B. Nardi
M. Barchiesi*
Affiliation:
Polytechnic University of Marche, Clinica di Psichiatria, Ancona, Italy
M. Martellini
Affiliation:
Polytechnic University of Marche, Clinica di Psichiatria, Ancona, Italy
M.G. Oriani
Affiliation:
Dipartimento di Salute Mentale Ancona ASUR Marche, Dipartimento di Salute Mentale Ancona ASUR Marche, Ancona, Italy
B. Nardi
Affiliation:
Polytechnic University of Marche, Clinica di Psichiatria, Ancona, Italy
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Anorexia nervosa (AN) is severe and debilitating psychiatric illness characterized by destructive weight loss behaviour, refusal to maintain body weight at or above minimal normal weight for age and height, intense fear of weight gain and disturbance in experience of body shape and weight.

Objectives

The purpose of this review is to investigate the state of art concerning the use of atypical antipsychotics (SGA) in the treatment of anorexia nervosa, comparing the efficacy and tolerability in female patients not selected by age.

Methods

A Medline enquiry of published articles from 2005 to October 2015 was performed using the following Keywords: “anorexia nervosa; pharmacological treatment; atypical antipsychotics; olanzapine; risperidone; paliperidone; aripiprazole; quetiapine”. Reviews and RCT were also analyzed.

Results

No strong evidence of beneficial effects was found in using SGA in adults. The majority of studies focused on olanzapine, which seems to have, in some studies, only positive effect on body mass index, eating disorder symptoms and functional impairment. Risperidone doesn’t seem to have effect on body mass index. Olanzapine and risperidone increase the mean fasting glucose and insulin levels. In a recent study the main finding is represented by the positive effects of the adjunct of aripiprazole to antidepressants on eating-related obsessive-compulsive symptomatology.

Conclusions

In conclusion, in our review we observed that research in treatment with SGA of AN is still far away from finding univocal conclusions.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EV572
Information
European Psychiatry , Volume 33 , Issue S1: Abstracts of the 24th European Congress of Psychiatry , March 2016 , pp. S430
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.